Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microdosing LSD for ADHD and Emotion Regulation
2025-520906-36-00Phase 2Withdrawn
- Sponsor
- Maastricht University
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Lysergide in attention deficit hyperactivity disorder (ADHD), sponsored by Maastricht University. Primary endpoints: ADHD symptoms, emotion regulation and 1 more. Planned start May 2026; status: withdrawn.
02
Drugs
Lysergide
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2025-520906-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520906-36-00.